Targeting Cervical Cancer

Cervical cancer is one of the most common cancers in women. Conventional treatment approaches have limitations such as serious side effects and toxicities. Currently, tumor-targeted delivery of anticancer drugs represents one of the most appropriate options to achieve optimal outcomes from the treatment and improve the quality of life. As an acknowledged targeted delivery services provider, Creative Biolabs is committed to providing the most comprehensive targeted delivery services for cervical cancer.

Cervical Cancer

Cervical cancer is a common malignancy in females, with an annual incidence of more than 450 000 worldwide and is the third most common cause of cancer-related deaths. Most cervical cancer cases are diagnosed at the advanced stage, which is closely associated with high mortality. To date, all cervical cancers are caused by human papillomaviruses (HPVs). Since HPVs have been found to be involved in the cause of cervical cancer in the 1970s, more than 100 types of HPV have been found. Currently, only 12 types of HPV have been involved in causing cancer. Among these HPV types, HPV16 and HPV18 are together responsible for about 70% of cervical cancers. However, the mechanisms of cancer caused by HPVs have not been fully revealed. In most cases, the reason of cancer occurs attributing to HPV oncogenes E5, E6 and E7 increase cell proliferation and decrease apoptosis by altering multiple intracellular signaling pathways.

Fig.1 The role of lncRNAs and circRNAs in cervical cancer.¹

Delivery System Targeting Cervical Cancer

Conventional cervical cancer treatment options include chemotherapy, surgery and radiation therapy with several side effects and toxicities. In recent years, drug delivery systems owing to their unique properties have been extensively investigated for anticancer drug delivery. A large number of studies of localized drug delivery strategies have been generated to treat cervical cancer.

Fig.2 Systemic drug delivery systems used in cervical cancer.²

Folate receptor is a potential therapeutic target in cervical cancer since its overexpression in human cervical cancer cells. Nanoparticles (NPs) were conjugated with folic acid and loaded with drugs, which increased the specificity of chemotherapeutic drugs up to 10-fold greater than control NPs without drug in cervical cancer cells. Polymeric micelles are important in cancer therapeutic applications given theirs in vivo stability, ability to solubilize water-insoluble drugs, prolongation of blood circulation time, and small size. For example, polymeric composite micelles were targeted with folic acid and loaded with paclitaxel, which can significantly inhibit tumor growth and caused cervical cancer tumors cell apoptosis both in vitro and in vivo. Transferrin-targeted liposomes are more specific in the delivery of paclitaxel to cervical cancer cell lines. Research results showed liposomes targeted with folic acid and transferrin had high cell association, penetration and efficacy of delivering doxorubicin.

What Can We Do for You?

Targeted drug delivery systems present various advantages in cancer treatment, such as allowing passive drug targeting to achieve high drug concentration at the target site, sustained and controlled release behavior, improve therapeutic outcomes and minimize side effects. Now Creative Biolabs offers variuos optimized module delivery systems to target cervical cancer, our high-quality services and products will meet the specific needs of our customers. For more details and information, please feel free to contact us.

References

1. Heidari-Ezzati, Sama, et al. "The role of long non-coding RNAs and circular RNAs in cervical cancer: modulating miRNAs function." Frontiers in Cell and Developmental Biology 12 (2024): 1308730.
2. Ordikhani, Farideh, et al. "Drug delivery approaches for the treatment of cervical cancer." Pharmaceutics 8.3 (2016): 23.

Our services are For Research Use Only. We do not provide services to individuals.